Experimental Prophylaxis Beneficial for Patients Undergoing HSCT

FRIDAY, June 23, 2023 -- For patients with hematologic cancer undergoing allogeneic hematopoietic stem-cell transplantation (HSCT), graft-versus-host-disease (GVHD)-free, relapse-free survival is more common among those receiving...